Moomoo AIのまとめ
Exicure, Inc., a biotechnology company, has received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department due to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company failed to file its annual report (Form 10-K) for the year ended December 31, 2023, by the extended deadline of May 20, 2024, and also did not file its quarterly report (Form 10-Q) for the first quarter of 2024. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders. As a result, Nasdaq plans to suspend trading of Exicure's common stock at the opening of business on May 30, 2024, unless the company files an appeal by May 28, 2024. Exicure intends to appeal the delisting and request a stay of suspension while it works to regain compliance. The company is actively working to complete and file the overdue reports and to hold a combined Annual Meeting for 2023 and 2024 as soon as possible. However, there is no assurance that Exicure will be able to regain compliance or be successful in its appeal to Nasdaq.
Exicure, Inc., a biotechnology company, has received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department due to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company failed to file its annual report (Form 10-K) for the year ended December 31, 2023, by the extended deadline of May 20, 2024, and also did not file its quarterly report (Form 10-Q) for the first quarter of 2024. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders. As a result, Nasdaq plans to suspend trading of Exicure's common stock at the opening of business on May 30, 2024, unless the company files an appeal by May 28, 2024. Exicure intends to appeal the delisting and request a stay of suspension while it works to regain compliance. The company is actively working to complete and file the overdue reports and to hold a combined Annual Meeting for 2023 and 2024 as soon as possible. However, there is no assurance that Exicure will be able to regain compliance or be successful in its appeal to Nasdaq.
バイオテクノロジー会社のエクシキュア株式会社は、Nasdaq Listing Qualifications Departmentからスタッフ・デリスティング決定を受け、Nasdaq Listing Rule 5250(c)(1)に違反したため、普通株式の取引を2024年5月30日のビジネス開始時に停止する予定です。同社は、2023年12月31日の年次報告書（フォーム10-K）を2024年5月20日の拡張期限までに提出せず、2024年第1四半期の四半期報告書（フォーム10-Q）も提出していませんでした。加えて、Exicureは2023年の株主総会を開催していません。その結果、同社が5月28日まで...すべて展開
バイオテクノロジー会社のエクシキュア株式会社は、Nasdaq Listing Qualifications Departmentからスタッフ・デリスティング決定を受け、Nasdaq Listing Rule 5250(c)(1)に違反したため、普通株式の取引を2024年5月30日のビジネス開始時に停止する予定です。同社は、2023年12月31日の年次報告書（フォーム10-K）を2024年5月20日の拡張期限までに提出せず、2024年第1四半期の四半期報告書（フォーム10-Q）も提出していませんでした。加えて、Exicureは2023年の株主総会を開催していません。その結果、同社が5月28日までに控訴しない場合、NasdaqはExicureの普通株式の取引を停止する予定です。Exicureはデリスティングを控訴し、停止の停止を要求する予定であり、コンバインドされた2023年および2024年の株主総会をできるだけ早く開催するために未提出報告書の完成と提出に取り組んでいます。ただし、Exicureがコンプライアンスを回復できるか、Nasdaqへの控訴で成功できるかどうかは保証されていません。
役に立った
役に立たない
